|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Athersys, Inc. Release: Publication Indicates That MultiStem Treatment May Reduce Inflammation and Promote Reparative Processes Following Acute Brain Injury
10/10/2012 9:52:13 AM
CLEVELAND, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the publication of an article in the peer-reviewed scientific journal, Journal of Neuroinflammation, that describes the results of a preclinical study evaluating the administration of MultiStem® cell therapy for the treatment of traumatic brain injury (TBI) in rodents. The article, authored by investigators from The University of Texas Health Science Center at Houston (UTHealth), together with scientists from Athersys, describes preclinical study results demonstrating that administration of MultiStem cells modulates the inflammatory environment that follows TBI, by reducing immune cell and cytokine activity associated with inflammation.
|
|
|
|
|
|
|
|
|
|
|